Our Office +972-8-9301-015|office@biokine.com
Biokine Therapeutics Biokine Therapeutics
  • Home
  • About Biokine
    • Company Profile
    • Managment Team
    • Board of Directors
  • Pipeline
    • clinical
    • Pre-clinical
  • News & Events
  • Partnering
    • Investors
  • Contact
Biokine Therapeutics Biokine Therapeutics
  • Home
  • About Biokine
    • Company Profile
    • Managment Team
    • Board of Directors
  • Pipeline
    • clinical
    • Pre-clinical
  • News & Events
  • Partnering
    • Investors
  • Contact

BioLineRx Discloses Positive Correlative Data from Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016

  • Home
  • Clinical Program BL8040
  • BioLineRx Discloses Positive Correlative Data from Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016
Previous Next

BioLineRx Discloses Positive Correlative Data from Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016

2018-10-10T17:36:16+00:00November 3rd, 2016|Clinical Program BL8040|
Copyright © 2019 Biokine LTD | All Rights Reserved |
Site By: Psik Advertising